

CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management

Chronic Lymphocytic Leukemia (CLL) TOOLKIT

Resource	Web Address
Agency for Healthcare Research and Quality (AHRQ). The SHARE Approach: A Model for Shared Decision Making. April 2016.	www.ahrq.gov/sites/default/files/publications/files/share-approach_factsheet.pdf
Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. <i>N Eng J Med</i> . 2020;383:498-500.	https://www.nejm.org/doi/full/10.1056/NEJMc2005943
Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncol</i> . 2020;21:1188-1200.	https://pubmed.ncbi.nlm.nih.gov/32888452/
American Cancer Society (ACS). Cancer Facts & Figures 2021. Accessed August 17, 2021.	https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html
American Cancer Society (ACS). Chronic Lymphocytic Leukemia (CLL). Accessed August 17, 2021.	https://www.cancer.org/cancer/chronic-lymphocytic-leukemia.html
Andreani G, Carrà G, Lingua MF, et al. Tumor suppressors in chronic lymphocytic leukemia: From lost partners to active targets. <i>Cancers (Basel)</i> . 2020;12:629.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139490/
Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Adv</i> . 2019;3:1553-1562.	https://pubmed.ncbi.nlm.nih.gov/31088809/

Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> . 2020;34:787-798.	https://pubmed.ncbi.nlm.nih.gov/31628428/
Byrd JC, et al. Up to 7 Years of follow-up of single-agent ibrutinib in the phase 1b/2 PCYC-1102 trial of first line and relapsed/refractory patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Blood</i> . 2018;132(suppl 1):3133.	https://ashpublications.org/blood/article/132/Supplement%201/3133/263863/Up-to-7-Years-of-Follow-up-of-Single-Agent
Byrd JC, Furman RR, Coutre S, et al. Up to 7 years of follow-up of single-agent ibrutinib in the phase 1b/2 PCYC-1102 trial of first line and relapsed/refractory patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Blood</i> . 2018;132(suppl 1):3133.	https://ashpublications.org/blood/article/132/Supplement%201/3133/263863/Up-to-7-Years-of-Follow-up-of-Single-Agent
Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase 1b/II PCYC-1102 study. <i>Clin Cancer Res</i> . 2020;26:3918-3927.	https://pubmed.ncbi.nlm.nih.gov/32209572/
Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. <i>N Engl J Med</i> . 2016;374:323-332.	https://www.ncbi.nlm.nih.gov/pubmed/26641137
Byrd JC, Hillman P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. <i>J Clin Oncol</i> . 2021;39(15 suppl):7500.	https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.7500
Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. <i>N Engl J Med</i> . 2013;369:1278-1279.	https://pubmed.ncbi.nlm.nih.gov/24066758/

Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naïve chronic lymphocytic leukemia. <i>Blood</i> . 2021;137:3327-3338.	https://pubmed.ncbi.nlm.nih.gov/33786588/
Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib In treatment-naïve chronic lymphocytic leukemia: Mature results from phase 2 study demonstrating durable remissions and long-term tolerability. <i>J Clin Oncol</i> 2020;38(15_suppl):8024.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8024
Copiktra® (duvelisib). Prescribing Information. Verastem, Inc; July 2019.	https://copiktra.com/pdf/verastem/COPIKT-RA-PI-072019.pdf
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. <i>Blood</i> . 1999;94:1840-1847.	https://pubmed.ncbi.nlm.nih.gov/10477712/
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. <i>N Engl J Med</i> . 2000;343:1910-1916.	https://www.ncbi.nlm.nih.gov/pubmed/11136261
Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. <i>Lancet Oncol</i> . 2016;17:928-942.	https://pubmed.ncbi.nlm.nih.gov/27216274/

Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with cludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). <i>Blood</i>. 2014;124:19.	https://ashpublications.org/blood/article/124/21/19/89819/Frontline-Chemoimmunotherapy-with-Fludarabine-F
Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. <i>N Engl J Med</i>. 2019;380:2225-2236.	https://www.nejm.org/doi/full/10.1056/NEJMoa1815281
Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i>. 2018;132:2446-2455.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284216/
Ghia P, Pluta A, Wach M, et al. Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results. <i>J Clin Oncol</i>. 2020;38(15 suppl):8015.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8015
Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. <i>J Clin Oncol</i>. 2020;38:2849-2861.	https://pubmed.ncbi.nlm.nih.gov/32459600/
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>N Engl J Med</i>. 2014;370:1101-1110.	https://www.nejm.org/doi/full/10.1056/nejmoa1313984

Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. <i>Blood</i> . 2008;111:5446-5456.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972576/
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> . 2018;131:2745-2760.	https://pubmed.ncbi.nlm.nih.gov/29540348/
Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. <i>Blood</i> . 1999;94:1848-1854.	https://www.ncbi.nlm.nih.gov/pubmed/10477713
Herman SEM, Montreveta A, Niemann CU, et al. Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. <i>Clin Cancer Res</i> . 2017;23:2831-2841.	https://clincancerres.aacrjournals.org/content/23/11/2831
Imbruvica® (ibrutinib). Prescribing Information. Pharmacyclics LLC; December 2020.	https://imbruvica.com/files/prescribing-information.pdf
Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncol</i> . 2018;19:65-75.	https://pubmed.ncbi.nlm.nih.gov/29246803/
Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III Study. <i>J Clin Oncol</i> . 2020;38:4042-4054.	https://pubmed.ncbi.nlm.nih.gov/32986498/

Mato A, Nabhan C, Lamanna N, et al. The Connect CLL Registry: Final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Adv.</i> 2020;4:1407-1418.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160291/
Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. <i>Clin Cancer Res.</i> 2020;26:3589-3596.	https://pubmed.ncbi.nlm.nih.gov/32198151/
Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2019;20:43-56.	https://pubmed.ncbi.nlm.nih.gov/30522969/
National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®) – Health Professional Version. Updated January 25, 2021.	https://www.cancer.gov/types/leukemia/hp/ctl-treatment-pdq
National Community Oncology Dispensing Association (NCODA). Suyko J. Positive quality intervention: Venetoclax risk stratification, dosing, and dispensing procedure. Updated April 22, 2021.	https://www.ncoda.org/venetoclax-dispensing-procedure/
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 4.2021.	https://www.nccn.org/professionals/physician_gls/pdf/ctl.pdf
O’Brien, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. <i>Blood.</i> 2018;131(17):1910-1919.	https://ashpublications.org/blood/article/131/17/1910/36756/Single-agent-ibrutinib-in-treatment-naive-and
Patel K, Danilov AV, Pagel JM. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. <i>Blood.</i> 2019;134:1573-1577.	https://pubmed.ncbi.nlm.nih.gov/31554637/

Roeker LE, Dreger P, Brown JR, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Adv.</i> 2020;4:3977-3989.	https://pubmed.ncbi.nlm.nih.gov/32841336/
Rozovski U, Keating MJ, Estrov Z. Why is the immunoglobulin heavy chain gene mutation status a prognostic indicator in chronic lymphocytic leukemia? <i>Acta Haematol.</i> 2018;140:51-54.	https://pubmed.ncbi.nlm.nih.gov/30114695/
Seymour JF, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. <i>N Engl J Med.</i> 2018;378:1107-1120.	https://www.ncbi.nlm.nih.gov/pubmed/29562156
Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. <i>N Engl J Med.</i> 2019;381:432-443.	https://www.nejm.org/doi/full/10.1056/nejmoa1817073
Sharman JP, Banerji V, Fogiatto LM, et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL). <i>Blood.</i> 2019;134(suppl 1):31.	https://ashpublications.org/blood/article/134/Supplement_1/31/427832/ELEVATE-TN-Phase-3-Study-of-Acalabrutinib-Combined
Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. <i>J Clin Oncol.</i> 2019;37:1391-1402.	https://pubmed.ncbi.nlm.nih.gov/30995176/

Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. <i>Blood</i> . 2014;124:330.	https://ashpublications.org/blood/article/124/21/330/97718/Second-Interim-Analysis-of-a-Phase-3-Study-of
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. <i>Lancet</i> . 2020;395:1278-1291.	https://pubmed.ncbi.nlm.nih.gov/32305093/
Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. <i>Blood</i> . 2016;127:303-309.	https://pubmed.ncbi.nlm.nih.gov/26492934/
Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. <i>Clin Lymphoma Myeloma Leuk</i> . 2014;14(5):335-342	https://pubmed.ncbi.nlm.nih.gov/24650973/
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. <i>N Engl J Med</i> . 2018;;379:2517-2528.	https://pubmed.ncbi.nlm.nih.gov/30501481/
Zydelig®(idelalisib). Prescribing Information. Gilead Sciences, Inc; October 2020.	https://www.gilead.com/~media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf

CATALYST: A Virtual Reality View of Genomics, Targeted Therapeutic Options, and Treatment Sequencing for the Management of Hematologic Malignancies

**Acute Myeloid Leukemia (AML)
TOOLKIT**

Resource	Web Address
American Cancer Society (ACS). Acute Myeloid Leukemia (AML) in Adults. Accessed August 17, 2021.	https://www.cancer.org/cancer/acute-myeloid-leukemia.html
Onureg®(azacitidine). Prescribing Information. Celgene Corp; May 2021.	https://packageinserts.bms.com/pi/pi_onureg.pdf
Büchner T, Schlenk RF, Schaich M, et al. Acute Myeloid Leukemia (AML): Different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. <i>J Clin Oncol</i> . 2012;30:3604-3610.	https://pubmed.ncbi.nlm.nih.gov/22965967/
Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ. Quality of life from the perspective of the patient with acute myeloid leukemia. <i>Cancer</i> . 2018;124:145-152.	https://pubmed.ncbi.nlm.nih.gov/28881384/
Burnett AK, Hills RK, Russell N. Twenty five years of UK trials in acute myeloid leukaemia: What have we learned? <i>Br J Haematol</i> . 2020;188:86-100	https://pubmed.ncbi.nlm.nih.gov/31828788/
Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. <i>Cancer</i> . 2007;109:1114-1124.	https://pubmed.ncbi.nlm.nih.gov/17315155/

Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. <i>Lancet</i>. 2012;379:1508-1516.	https://pubmed.ncbi.nlm.nih.gov/22482940/
Cheson BD, Bennett JM, Kopecky, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. <i>J Clin Oncol</i>. 2003;21:4642-4649.	https://pubmed.ncbi.nlm.nih.gov/14673054/
Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i>. 2019;33:379-389.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365492/
Vyxeos®(daunorubicin + cytarabine). Prescribing Information. Jazz Pharmaceuticals, Inc; March 2021.	http://pp.jazzpharma.com/pi/vyxeos.en.USP1.pdf
DiNardo CD, Jonas B, Pullarkat V, et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine In treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy-Viale-A. Presented at European Hematology Association Annual Congress. June 14, 2020.	https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. <i>N Engl J Med</i>. 2018;378:2386-2398.	https://www.ncbi.nlm.nih.gov/pubmed/29860938

DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. <i>N Engl J Med</i> . 2020;383:617-629.	https://pubmed.ncbi.nlm.nih.gov/32786187/
DiNardo CD, Stein AS, Stein EM, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia, <i>J Clin Oncol</i> . 2021;39:57-65	https://pubmed.ncbi.nlm.nih.gov/33119479/
DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study. <i>Blood</i> . 2019;134(suppl. 1):643.	https://ashpublications.org/blood/article/134/Supplement_1/643/426571/Enasidenib-Plus-Azacitidine-Significantly-Improves
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> . 2017;129:424-447.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291965/
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> . 2015;126:291-299.	https://pubmed.ncbi.nlm.nih.gov/25987659/
Idhifa®(enasidenib). Prescribing Information. Celgene Corp; November, 2020.	www.idhifa.com/prescribing-information/
Food and Drug Administration. FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia [press release]. July 20, 2018.	https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-relapsed-or-refractory-acute-myeloid-leukemia

Food and Drug Administration. FDA approves Mylotarg for treatment of acute myeloid leukemia [press release]. September 1, 2017.	https://www.fda.gov/news-events/press-announcements/fda-approves-mylotarg-treatment-acute-myeloid-leukemia
Mylotarg™(gemtuzumab ozogamicin). Prescribing Information. Pfizer; August 2021.	http://labeling.pfizer.com/ShowLabeling.aspx?id=9548
Gemtuzumab Ozogamicin. Overview. March 9, 2018.	http://www.ncbi.nlm.nih.gov/books/NBK548438/pdf/Bookshelf_NBK548438.pdf
Xospata®(gilteritinib). Prescribing Information. Astellas Pharma US, Inc; May 2019.	https://astellas.us/docs/xospata.pdf
Daurismo™(glasdegib). Prescribing Information. Pfizer; March, 2020.	http://labeling.pfizer.com/ShowLabeling.aspx?id=11336
Gottesman MM. Mechanisms of cancer drug resistance. <i>Annu Rev Med.</i> 2002;53:615-627.	https://pubmed.ncbi.nlm.nih.gov/11818492/
Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncol.</i> 2014;15:986-996.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137593/
Horton SJ, Huntly BJP. Recent advances in acute myeloid leukemia stem cell biology. <i>Haematologica.</i> 2012;97:966-974.	https://pubmed.ncbi.nlm.nih.gov/22511496/
Ingram I. FDA approves gemtuzumab ozogamicin for acute myeloid leukemia. <i>Cancer Network.</i> Published September 16, 2017.	https://www.cancernetwork.com/view/fda-approves-gemtuzumab-ozogamicin-acute-myeloid-leukemia
Tibsovo®(ivosidenib). Prescribing Information. Servier Pharmaceuticals LLC; May 2021.	www.tibsovo.com/pdf/prescribinginformation.pdf
Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. <i>Clin Cancer Res.</i> 2009;15:1126-1132.	https://pubmed.ncbi.nlm.nih.gov/19228717/

Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. <i>J Clin Oncol</i> . 2012;30:2670-2677.	https://pubmed.ncbi.nlm.nih.gov/22689805/
Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. <i>Blood</i> . 2014;123:3239-3246	https://pubmed.ncbi.nlm.nih.gov/24687088/
Lancet JE, UY GL, Cortes JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. <i>J Clin Oncol</i> . 2016;34(15_suppl):7000.	https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.7000
Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. <i>J Clin Oncol</i> . 2018;36:2684-2692	https://pubmed.ncbi.nlm.nih.gov/30024784/
Levis M. Targeting IDH: The next big thing in AML. <i>Blood</i> . 2013;122:2770-2771.	https://pubmed.ncbi.nlm.nih.gov/24136078/
Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. <i>N Engl J Med</i> . 2009;361:1235-1248	https://pubmed.ncbi.nlm.nih.gov/19776405/

Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. <i>Mol Cancer Ther.</i> 2006;5:1854-1863.	https://pubmed.ncbi.nlm.nih.gov/16891472/
Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. <i>Arch Intern Med.</i> 2002;162:1597-1603.	https://pubmed.ncbi.nlm.nih.gov/12123403/
Rydapt®(midostaurin). Prescribing Information. Novartis Pharmaceuticals Corp; April 2021.	https://www.novartis.us/sites/www.novartis.us/files/rydapt.pdf
National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML). Accessed August 17, 2021.	https://seer.cancer.gov/statfacts/html/amyl.html
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 3.2021.	https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
National Quality Forum (NQF). <i>National Quality Partners Playbook™: Shared Decision Making in Healthcare</i> . Washington, DC: NQF;2018.	https://www.qualityforum.org/National_Quality_Partners_Shared_Decision_Making_Action_Team.aspx
O'Donnell MR, Tallman MS, Abboud CN, et al. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>J Natl Compr Canc Netw.</i> 2017;15:926-957.	https://jnccn.org/view/journals/jnccn/15/7/article-p926.xml
Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era? <i>Cancer.</i> 2011;117:3293-3304.	https://pubmed.ncbi.nlm.nih.gov/21319142/

Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory <i>FLT3</i>-mutated AML. <i>N Engl J Med</i>. 2019;381:1728-1740.	https://pubmed.ncbi.nlm.nih.gov/31665578/
Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020. Accessed August 17, 2021.	http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx
Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. <i>Am J Hematol</i>. 2021;96:208-217.	https://pubmed.ncbi.nlm.nih.gov/33119898/
Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. <i>Blood</i>. 1981;58:1203-1212.	https://pubmed.ncbi.nlm.nih.gov/6946847/
Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the sonic hedgehog signaling pathway: Review of smoothened and GLI inhibitors. <i>Cancers (Basel)</i>. 2016;8:22.	https://pubmed.ncbi.nlm.nih.gov/26891329/
Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. Acute myeloid leukemia: A retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. <i>Curr Med Res Opin</i>. 2017;33:519-527.	https://pubmed.ncbi.nlm.nih.gov/27966377/
Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i>. 2020;135:463-471.	https://pubmed.ncbi.nlm.nih.gov/31841594/

Roboz GJ, Montesinos P, Selleslag D, et al. Design of the randomized, phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncol</i> . 2016;12:293-302.	https://pubmed.ncbi.nlm.nih.gov/26785287/
Solis-Moreira J. Azacitidine tablets approved by FDA for patients with AML in first remission. <i>JNCCN 360</i> . Published September 3, 2020.	https://jnccn360.org/aml/news/azacitidine-tablets-approved-by-fda-for-patients-with-aml-in-first-remission/
Stein E, Dinardo CD, Jang JH, et al. AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. <i>J Clin Oncol</i> . 2018;36(suppl15):TPS7074.	https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS7074
Stein EM, Dinardo CD, Pollyea DA, et al. Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia. <i>Blood</i> . 2017;130:722-731.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. <i>N Engl J Med</i> . 2017;377:454-464.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754190/
Storey S, Gray TF, Bryant AL. Comorbidity, physical function, and quality of life in older adults with acute myeloid leukemia. <i>Curr Geriatr Rep</i> . 2017;6:247-254.	https://pubmed.ncbi.nlm.nih.gov/29479516/
National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML). Accessed August 17, 2021.	https://seer.cancer.gov/statfacts/html/amyl.html

Venclexta®(venetoclax). Prescribing Information. AbbVie Inc; November 2020.	https://www.rxabbvie.com/pdf/venclexta.pdf
Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. <i>N Engl J Med</i> . 2020;383:2526-2537.	https://pubmed.ncbi.nlm.nih.gov/33369355/
Zeijlemaker W, Schuurhuis GJ. Minimal residual disease and leukemic stem cells in acute myeloid leukemia. In: Guenova M, Balatzenko G, eds. <i>Leukemia</i> . IntechOpen. May 2013:195-226.	https://www.intechopen.com/chapters/39017